Wolfgang von der Saal
Roche Diagnostics
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Wolfgang von der Saal.
Journal of Medicinal Chemistry | 2011
Michael Prime; Stephen Martin Courtney; Frederick Arthur Brookfield; Richard W. Marston; Victoria Walker; Justin Warne; Andrew E. Boyd; Norman Kairies; Wolfgang von der Saal; Anja Limberg; Guy Georges; Richard A. Engh; Bernhard Goller; Petra Rueger; Matthias Rueth
The inhibition of Aurora kinases in order to arrest mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells has generated significant discussion within the literature. We report a novel class of Aurora kinase inhibitors based upon a phthalazinone pyrazole scaffold. The development of the phthalazinone template resulted in a potent Aurora-A selective series of compounds (typically >1000-fold selectivity over Aurora-B) that display good pharmacological profiles with significantly improved oral bioavailability compared to the well studied Aurora inhibitor VX-680.
Bioorganic & Medicinal Chemistry Letters | 1997
Wolfgang von der Saal; Ralf Kucznierz; Herbert Leinert; Richard A. Engh
Abstract During screening for novel thrombin inhibitors it was discovered that the 4-aminopyridine derivative 1 inhibits human α-thrombin competitively and selectively. The 4-aminopyridine moiety itself is most likely the major determinant of the selectivity due to the increased hydrophobicity of the S1 pocket in thrombin compared to trypsin and plasmin. Optimization led to the selective thrombin inhibitor 14 with an inhibition constant, Ki of 70 nM.
Bioorganic & Medicinal Chemistry Letters | 1998
Ingo R. Weber; Richard Neidlein; Wolfgang von der Saal; Frank Grams; Herbert Leinert; Klaus Strein; Richard A. Engh; Ralf Kucznierz
Based on the structures of aminopyridine thrombin inhibitors (1), a series of aminoalkyl- and guanidinoalkyl-substituted diarylsulfonamides were prepared. The most potent derivative, N-[3-(4-guanidinobutoxy)-5-methyl-phenyl]-benzenesulfonamide (6c) had Ki = 0.18 microM for thrombin and did not inhibit trypsin, plasmin, or factor Xa. Comparison of the X-ray structures of the thrombin/1b and the thrombin/6c complexes revealed important aspects which govern the binding of such diarylsulfonamides to thrombin.
Synthetic Communications | 1999
Ralf Kucznierz; Joachim Dipl-chemi Dickhaut; Herbert Leinert; Wolfgang von der Saal
Abstract Improved procedures for large scale preparation of oxy-substituted isoquinoiines are reported. Moreover, a simple and convenient protocol for alkaline work-up of titanium containing reaction mixtures is given, which is expected to be of general interest even for reactions on a technical scale.
Journal of Medicinal Chemistry | 2002
Olivier Roche; Petra Schneider; Jochen Zuegge; Wolfgang Guba; Manfred Kansy; Alexander Alanine; Konrad Bleicher; Franck Danel; Eva-Maria Gutknecht; Mark Rogers-Evans; Werner Neidhart; Henri Stalder; Michael Patrick Dillon; Eric Brian Sjogren; Nader Fotouhi; Paul Gillespie; Robert Alan Goodnow; William Harris; Phil Jones; Mikio Taniguchi; Shinji Tsujii; Wolfgang von der Saal; Gerd Zimmermann; Gisbert Schneider
Structure | 1996
Richard A. Engh; Hans Brandstetter; Gudrun Sucher; Andreas Eichinger; Ulrich Baumann; Wolfram Bode; Robert Huber; Thomas Poll; Rainer Rudolph; Wolfgang von der Saal
Archive | 1990
Wolfgang von der Saal; Harald Zilch; Erwin Böhm
Archive | 1986
Alfred Mertens; Wolfgang von der Saal; Walter-Gunar Friebe; Bernd Muller-Beckmann; Gisbert Sponer
Journal of Medicinal Chemistry | 1989
Wolfgang von der Saal; Jens Peter Hoelck; Wolfgang Kampe; Alfred Mertens; Bernd Mueller-Beckmann
Archive | 2002
Guy Georges; Adelbert Grossmann; Olaf Mundigl; Wolfgang von der Saal; Tim Sattelkau